Important note

This AI stock analysis for Esperion Therapeutics is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

Esperion Therapeutics - AI Stock Analysis

Analysis generated May 21, 2025

Esperion Therapeutics, Inc. is a pharmaceutical company headquartered in Ann Arbor, Michigan. The company specializes in developing and commercializing oral medicines for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Their key product, Nexletol (bempedoic acid), has shown promise as a new lipid-lowering treatment, particularly for patients who inadequately respond to or cannot tolerate statins. Esperion aims to cater to the unmet need in cardiovascular disease management by providing alternative cholesterol-lowering therapies.

Fundamental Analysis

Esperion reported a revenue of $65 million for the last quarter. This represents a decrease of 5.96% compared to the previous quarter. More concerning is the 52.81% decrease in revenue compared to the same quarter last year, flagging potential structural issues or market challenges.

The net income for the last quarter stood at $40 million, an alarming decrease of 89.77% from the previous quarter and a staggering 166.30% drop compared to the same quarter last year. This suggests significant financial difficulties and could indicate either increasing operational costs or declining revenues, or both.

EBITDA for the last quarter was reported at $22 million, a concerning decrease of 353.81% from the previous quarter and a 129.44% decrease from the same quarter the previous year. Such dramatic declines in EBITDA highlight potential operational inefficiencies or declining profit margins.

Additionally, insider selling has been noted over the last couple of months, often seen as a bearish indicator, suggesting potential lack of confidence in the company’s short-term outlook by those who know it best.

Technical Analysis

Esperion Therapeutics’ current stock price is $0.91, signifying a 7.06% increase compared to a month ago, which shows a short-term positive trend. However, this is set against a 61.76% decrease compared to a year ago, raising concerns about the stock's long-term performance.

The Simple Moving Average (SMA10) is currently calculated at 0.82, higher than the previous SMA10 of 0.81, indicating a potential upward trend in stock prices. The Relative Strength Index (RSI) is at 46.8, suggesting a neutral market condition that neither oversold nor overbought.

Alternative Data Analysis

Regarding job postings and employee sentiment, Esperion Therapeutics has 12 open positions according to data from popular job boards. This represents a 33% increase in job openings over the past few months, signaling potential company expansion and growth. Employee sentiment about the business outlook is neutral, reflecting neither strong optimism nor pessimism among staff.

Analyzing customer acquisition data, the company’s website has attracted approximately 8,000 visitors, a 27% decrease over the last few months. This is concerning as it could indicate a diminishing customer base or lower market interest.

Customer engagement on social media reflects stagnation, with 2,100 followers on their Twitter page and no significant changes in recent months. Finally, AltIndex’s AI score—which evaluates a company’s stock based on various data analyses—gives Esperion Therapeutics a score of 42, translating to a 'hold' signal, suggesting modest confidence in the stock's performance.

Conclusion

Overall, the outlook for Esperion Therapeutics appears mixed. The company is seeing troubling trends in revenue, net income, and EBITDA, which reflect significant financial challenges. However, on the operational front, an increase in job postings could indicate future growth and expansion. While recent stock performance shows short-term gains, the long-term decline is worrying.

Considering the overall analysis, a cautious approach is warranted. The stock could be labeled a 'hold', reflecting the need for potential investors to await further clarity and stabilization in the company's financial metrics before making substantial investment commitments.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.